Oneness Biotech Co

Oneness Biotech Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Oneness Biotech Co (4743.TWO) as of Oct 30, 2026 is 46.59 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 34.23 % — a change of 36.09% (higher).

FCF Conversion

46.59 %

YoY

36.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Oneness Biotech Co is 2025 46.59 % . FCF Conversion Rate (FCF/EBITDA) of Oneness Biotech Co was 2024 34.23 % . It decreases by 36.09% higher compared to the previous year.

The Oneness Biotech Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
73.21 TWD
Jan 1, 2019
79.32 TWD
Jan 1, 2020
-1.93 TWD
Jan 1, 2021
94.27 TWD
Jan 1, 2022
-269.51 TWD
Jan 1, 2023
37.02 TWD
Jan 1, 2024
34.23 TWD
Jan 1, 2025
46.59 TWD
The Oneness Biotech Co FCF Conversion history
YEARFCF ConversionYoY
46.59 %+36.09%
34.23 %-7.54%
37.02 %-113.74%
-269.51 %-385.88%
94.27 %-4,976.08%
-1.93 %-102.44%
79.32 %+8.34%
73.21 %-76.21%
307.79 %-83.16%
1,827.73 %+732.61%
219.52 %-381.75%
-77.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oneness Biotech Co Stock analysis

What does Oneness Biotech Co do? Oneness Biotech Co., Ltd. generates revenue through the research and development of new drugs and the sale of pharmaceutical products and health products. The company focuses on health supplies, health food, and healthy food as its main products, which are distributed domestically. It also develops new drugs for treating chronic diabetic foot ulcers and anticancer drugs, targeting the domestic market for both its existing and new product lines. The firm's primary customers are domestic consumers seeking health and pharmaceutical solutions, including those requiring wound healing treatments for diabetic foot ulcers and anticancer therapies. Its product portfolio includes health supplies, health food, healthy food, and specialized drug developments, all sold within Taiwan's domestic market. Oneness Biotech's business model centers on developing and selling health and pharmaceutical products, with a particular emphasis on niche medical applications like diabetic foot ulcer treatments and cancer drugs. The company leverages its domestic distribution network to reach consumers interested in health-focused solutions and specialized medical treatments. Oneness Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oneness Biotech Co stock

FCF Conversion Rate (FCF/EBITDA) of Oneness Biotech Co is 46.59 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Oneness Biotech Co changed from 34.23 % to 46.59 %, representing a 36.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Oneness Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Oneness Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Oneness Biotech Co

All Key Metrics — Oneness Biotech Co